Chen‐Yen Lin

2.2k total citations · 2 hit papers
57 papers, 1.7k citations indexed

About

Chen‐Yen Lin is a scholar working on Immunology, Rheumatology and Dermatology. According to data from OpenAlex, Chen‐Yen Lin has authored 57 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Immunology, 22 papers in Rheumatology and 16 papers in Dermatology. Recurrent topics in Chen‐Yen Lin's work include Psoriasis: Treatment and Pathogenesis (34 papers), Spondyloarthritis Studies and Treatments (18 papers) and Dermatology and Skin Diseases (15 papers). Chen‐Yen Lin is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (34 papers), Spondyloarthritis Studies and Treatments (18 papers) and Dermatology and Skin Diseases (15 papers). Chen‐Yen Lin collaborates with scholars based in United States, Japan and Canada. Chen‐Yen Lin's co-authors include Susan Halabi, Catherine L Shuler, Philip J. Mease, Eric J. Small, Ellen B. Kaplan, Chin H. Lee, Masato Okada, Dafna Gladman, Christopher T. Ritchlin and Désirée van der Heijde and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of the Rheumatic Diseases.

In The Last Decade

Chen‐Yen Lin

54 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

2023 65 citations Ohsang Kwon, Maryanne M. Senna et al. American Journal of Clinical Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chen‐Yen Lin United States	20	893	566	426	386	357	57	1.7k
Bernardo A. Pons‐Estel Argentina	32	1.9k 2.1×	2.4k 4.2×	65 0.2×	540 1.4×	78 0.2×	97	3.8k
Lauren L. Ritterhouse United States	26	611 0.7×	272 0.5×	38 0.1×	62 0.2×	646 1.8×	69	2.8k
Johan Bratt Sweden	21	393 0.4×	952 1.7×	16 0.0×	370 1.0×	102 0.3×	38	1.4k
Eva van den Berg Netherlands	28	135 0.2×	183 0.3×	83 0.2×	846 2.2×	754 2.1×	88	2.6k
Deepak Khatry United States	15	320 0.4×	113 0.2×	24 0.1×	199 0.5×	739 2.1×	22	1.9k
Melanie J. McCoy Australia	16	324 0.4×	122 0.2×	27 0.1×	63 0.2×	164 0.5×	28	1.0k
Simon Cooper United Kingdom	8	733 0.8×	720 1.3×	174 0.4×	126 0.3×	42 0.1×	28	1.2k
Yuko Hashimoto Japan	19	180 0.2×	78 0.1×	41 0.1×	58 0.2×	221 0.6×	114	1.3k
Simon Cotterill United Kingdom	26	60 0.1×	352 0.6×	45 0.1×	107 0.3×	1.2k 3.3×	41	2.8k
Marije F. Bakker Netherlands	18	117 0.1×	711 1.3×	10 0.0×	236 0.6×	302 0.8×	37	1.5k

Countries citing papers authored by Chen‐Yen Lin

Since Specialization

Citations

This map shows the geographic impact of Chen‐Yen Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chen‐Yen Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chen‐Yen Lin more than expected).

Fields of papers citing papers by Chen‐Yen Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chen‐Yen Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chen‐Yen Lin. The network helps show where Chen‐Yen Lin may publish in the future.

Co-authorship network of co-authors of Chen‐Yen Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Chen‐Yen Lin. A scholar is included among the top collaborators of Chen‐Yen Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chen‐Yen Lin. Chen‐Yen Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tang, Xi, et al.. (2025). Tinea capitis in Hainan: a prospective study. Frontiers in Cellular and Infection Microbiology. 15. 1590315–1590315.

Lin, Chen‐Yen, et al.. (2024). Efficacy and Safety of Combination Therapy of Microneedling Radiofrequency, In‐Office and Home‐Based Topical Cysteamine in Refractory Melasma: A Split Face, Vehicle‐Control, Randomized Control Trial. Journal of Cosmetic Dermatology. 24(2). e16661–e16661. 2 indexed citations

Kwon, Ohsang, Maryanne M. Senna, Rodney Sinclair, et al.. (2023). Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). American Journal of Clinical Dermatology. 24(3). 443–451. 65 indexed citations breakdown →

Kaizar, Eloise, Chen‐Yen Lin, Douglas E. Faries, & Joseph A. Johnston. (2023). Reweighting estimators to extend the external validity of clinical trials: methodological considerations. Journal of Biopharmaceutical Statistics. 33(5). 515–543. 3 indexed citations

Blauvelt, Andrew, Nianwen Shi, Russel Burge, et al.. (2020). <p>Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab</p>. Patient Preference and Adherence. Volume 14. 517–527. 22 indexed citations

Korman, Neil J., William N. Malatestinic, Orin M. Goldblum, et al.. (2020). Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective. Journal of Dermatological Treatment. 33(2). 733–739. 11 indexed citations

Leonardi, Craig L., Kristian Reich, Peter Foley, et al.. (2020). Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and Therapy. 10(3). 431–447. 45 indexed citations

Blauvelt, Andrew, Nianwen Shi, Russel Burge, et al.. (2019). Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. Journal of the American Academy of Dermatology. 82(4). 927–935. 37 indexed citations

Amato, Dante, et al.. (2019). 592 Impact of scalp psoriasis on quality of life measurements at baseline and following treatment with ixekizumab. Journal of Investigative Dermatology. 139(5). S102–S102. 2 indexed citations

10.

Kavanaugh, Arthur, Alice B. Gottlieb, Akimichi Morita, et al.. (2019). The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Annals of the Rheumatic Diseases. 78(9). 1215–1219. 37 indexed citations

11.

Ryan, Caitriona, Alan Menter, Lyn Guenther, et al.. (2018). Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. British Journal of Dermatology. 179(4). 844–852. 85 indexed citations

12.

Armstrong, April W., Shonda A. Foster, Brian S. Comer, et al.. (2018). Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. BMC Dermatology. 18(1). 4–4. 26 indexed citations

13.

Romiti, Ricardo, et al.. (2017). Ixekizumab Treatment Improves Itching And Health-Related Quality (HRQOL) of Life In Psoriasis Patients In Latin America. Value in Health. 20(9). A807–A807. 5 indexed citations

14.

Malatestinic, William N., Beth Nordstrom, Jashin J. Wu, et al.. (2017). Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. Journal of Managed Care & Specialty Pharmacy. 23(3). 370–381. 16 indexed citations

15.

Mease, Philip J., Masato Okada, Mitsumasa Kishimoto, et al.. (2017). 397 Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis. Journal of Investigative Dermatology. 137(10). S260–S260. 7 indexed citations

16.

Bacci, Elizabeth D., Amy M. DeLozier, Chen‐Yen Lin, et al.. (2017). Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis. Health and Quality of Life Outcomes. 15(1). 239–239. 11 indexed citations

17.

Kimball, Alexa B., Thomas A. Luger, Alice B. Gottlieb, et al.. (2017). Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. Acta Dermato Venereologica. 98(1). 98–102. 22 indexed citations

18.

Bacci, Elizabeth D., Amy M. DeLozier, Chen‐Yen Lin, et al.. (2017). Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis. Health and Quality of Life Outcomes. 15(1). 237–237. 2 indexed citations

19.

Mease, Philip J., Désirée van der Heijde, Christopher T. Ritchlin, et al.. (2016). Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Annals of the Rheumatic Diseases. 76(1). 79–87. 431 indexed citations breakdown →

20.

Lin, Chen‐Yen & Susan Halabi. (2016). A simple method for deriving the confidence regions for the penalized Cox’s model via the minimand perturbation. Communication in Statistics- Theory and Methods. 46(10). 4791–4808. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact